Steven Cohen’s Point72 Asset Management disclosed a 5.2% stake in Design Therapeutics (DSGN), which represents over 2.94M shares. The filing with the SEC does not allow for activism.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics Reports Increased R&D Expenses Amid Net Loss
- Design Therapeutics: Hold Rating Amid Regulatory Hurdles and Financial Caution
- Design Therapeutics Advances GeneTAC Programs Amid FDA Hold
- Design Therapeutics reports Q2 EPS (34c), consensus (33c)
- Design Therapeutics Faces Financial Strain Amid International Trade Challenges